Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 3/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6973388 | 0.85 | TMEM97 (0.60) | SIGMAR1HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL24349700 | 0.84 | ABCB1 (0.70) | ABCB1ABCG2SIGMAR1HRH3OPRM1 | |
| SCHEMBL6512477 | 0.83 | HRH3 (0.68) | SIGMAR1HRH3 | |
| Hydrochloric Acid SCHEMBL7600991 | 0.82 | ABCB1 (0.68) | ABCB1ABCG2SIGMAR1HRH3OPRM1 | |
| SCHEMBL10361498 | 0.82 | SIGMAR1 (0.53) | ABCB1ABCG2SIGMAR1HRH3 | |
| SCHEMBL6501779 | 0.80 | DRD2 (0.46) | ABCB1ABCG2 | |
| SCHEMBL7743687 | 0.80 | ABCB1 (0.62) | ABCB1SIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL8900524 | 0.79 | PNMT (0.54) | SIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL21412795 | 0.79 | SIGMAR1 (0.59) | SIGMAR1HRH3 | |
| SCHEMBL1953020 | 0.79 | DRD2 (0.46) | ABCB1ABCG2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | ABCB1 699/4885ABCG2 436/4885SIGMAR1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.